Characterization of cytokine-encapsulated controlled-release microsphere adjuvants.

Controlled-release, injectable polymer microspheres provide a clinically feasible alternative to gene-modification for the local, sustained delivery of cytokines to tumors for cancer immunotherapy. Long-term release kinetics, bioactivity profiles, and stability of interleukin-2 (IL-2), interleukin-12 (IL-12), and granulocyte- macrophage colony-stimulating factor (GM-CSF)-encapsulated microspheres prepared by phase inversion nanoencapsulation (PIN) were evaluated. While all formulations released physiologically relevant quantities of cytokine for up to 30 days, the individual release kinetics were different. Recovery of specific activity after encapsulation was 40%, 60%, and 90%-that of pre-encapsulation levels for IL-2, GM-CSF and IL-12, respectively. Upon storage, the IL-12 microspheres rapidly lost activity, whereas IL-2 and GM-CSF microspheres remained stable for at least 9 weeks. These studies demonstrate that biochemical properties of microsphere formulations vary depending on the cytokine, and rigorous characterization of formulations is a prerequisite to in vivo testing.

[1]  Robert Langer,et al.  Advancing the field of drug delivery: taking aim at cancer. , 2003, Cancer cell.

[2]  G. Dranoff.  GM-CSF-secreting melanoma vaccines , 2003, Oncogene.

[3]  M. Sabel,et al.  Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. , 2002, Cancer research.

[4]  K. Griebenow,et al.  Protein spray freeze drying. 2. Effect of formulation variables on particle size and stability. , 2002, Journal of pharmaceutical sciences.

[5]  W. Friess,et al.  Modifying the Release of Gentamicin from Microparticles Using a PLGA Blend , 2002, Pharmaceutical development and technology.

[6]  M. Choti,et al.  Controlled Local Delivery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain Tumors and Liver Tumors , 2001, Pharmaceutical Research.

[7]  W. Somers,et al.  Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin‐12 , 2000, The EMBO journal.

[8]  M. Sabel,et al.  In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. , 2000, Cancer research.

[9]  R. Ceriani,et al.  Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. , 1999, Hybridoma.

[10]  Scott D. Putney,et al.  Improving protein therapeutics with sustained-release formulations , 1998, Nature Biotechnology.

[11]  E. Jaffee,et al.  Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. , 1993, Cancer research.

[12]  U. Hámmerling,et al.  Development and validation of a bioassay for interleukin-2. , 1992, Journal of pharmaceutical and biomedical analysis.

[13]  F. Podlaski,et al.  Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Jalil,et al.  Microencapsulation using poly(DL-lactic acid). III: Effect of polymer molecular weight on the release kinetics. , 1990, Journal of microencapsulation.

[15]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[16]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.